Large B-cell lymphoma of the leg: Clinical and pathologic characteristics in a North American series

Beth L. Brogan, John A. Zic, Marsha C Kinney, Judy Y. Hu, Katherine S. Hamilton, John P. Greer

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Background: Large B-cell lymphoma (LBCL) of the leg is an uncommon subset of primary cutaneous B-cell lymphoma that has been described in a series of European patients. Objective: Our purpose was to evaluate the clinical manifestation, diagnostic histopathology, immunophenotype, clinical course, and response to treatment of LBCL of the leg. Methods: We conducted a retrospective case series of 3 patients with primary LBCL of the leg. Results: The 3 elderly patients presented with progressive erythematous nodules on bilateral or unilateral lower extremities. All 3 patients had pre-existing peripheral edema or peripheral vascular disease. Histopathologic examination of the nodules showed dense lymphocytic infiltrates composed predominantly of large dysplastic lymphocytes that marked as B cells (CD20+). In 2 cases, the neoplastic cells were BCL-2 positive. All patients responded to initial therapy with localized electron beam radiation and chemotherapy but had disease progression. One patient had a complete and durable second response to anti-CD20 monoclonal antibody (rituximab). Conclusions: The patients described have similar clinical and histopathologic features to those previously described. There may be an association between LBCL and pre-existing lower-extremity vascular disease. Treatment of LBCL is difficult, but 1 patient responded well to systemic anti-CD20 monoclonal antibody.

Original languageEnglish (US)
Pages (from-to)223-228
Number of pages6
JournalJournal of the American Academy of Dermatology
Volume49
Issue number2
DOIs
StatePublished - Aug 1 2003
Externally publishedYes

Fingerprint

B-Cell Lymphoma
Leg
Lower Extremity
Monoclonal Antibodies
Peripheral Vascular Diseases
Vascular Diseases
Disease Progression
Edema
B-Lymphocytes
Therapeutics
Lymphocytes
Electrons
Radiation
Drug Therapy
Skin

ASJC Scopus subject areas

  • Dermatology

Cite this

Large B-cell lymphoma of the leg : Clinical and pathologic characteristics in a North American series. / Brogan, Beth L.; Zic, John A.; Kinney, Marsha C; Hu, Judy Y.; Hamilton, Katherine S.; Greer, John P.

In: Journal of the American Academy of Dermatology, Vol. 49, No. 2, 01.08.2003, p. 223-228.

Research output: Contribution to journalArticle

Brogan, Beth L. ; Zic, John A. ; Kinney, Marsha C ; Hu, Judy Y. ; Hamilton, Katherine S. ; Greer, John P. / Large B-cell lymphoma of the leg : Clinical and pathologic characteristics in a North American series. In: Journal of the American Academy of Dermatology. 2003 ; Vol. 49, No. 2. pp. 223-228.
@article{fce225757c1b4e3fb7ef70cc7a384d3b,
title = "Large B-cell lymphoma of the leg: Clinical and pathologic characteristics in a North American series",
abstract = "Background: Large B-cell lymphoma (LBCL) of the leg is an uncommon subset of primary cutaneous B-cell lymphoma that has been described in a series of European patients. Objective: Our purpose was to evaluate the clinical manifestation, diagnostic histopathology, immunophenotype, clinical course, and response to treatment of LBCL of the leg. Methods: We conducted a retrospective case series of 3 patients with primary LBCL of the leg. Results: The 3 elderly patients presented with progressive erythematous nodules on bilateral or unilateral lower extremities. All 3 patients had pre-existing peripheral edema or peripheral vascular disease. Histopathologic examination of the nodules showed dense lymphocytic infiltrates composed predominantly of large dysplastic lymphocytes that marked as B cells (CD20+). In 2 cases, the neoplastic cells were BCL-2 positive. All patients responded to initial therapy with localized electron beam radiation and chemotherapy but had disease progression. One patient had a complete and durable second response to anti-CD20 monoclonal antibody (rituximab). Conclusions: The patients described have similar clinical and histopathologic features to those previously described. There may be an association between LBCL and pre-existing lower-extremity vascular disease. Treatment of LBCL is difficult, but 1 patient responded well to systemic anti-CD20 monoclonal antibody.",
author = "Brogan, {Beth L.} and Zic, {John A.} and Kinney, {Marsha C} and Hu, {Judy Y.} and Hamilton, {Katherine S.} and Greer, {John P.}",
year = "2003",
month = "8",
day = "1",
doi = "10.1067/S0190-9622(03)00889-2",
language = "English (US)",
volume = "49",
pages = "223--228",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Large B-cell lymphoma of the leg

T2 - Clinical and pathologic characteristics in a North American series

AU - Brogan, Beth L.

AU - Zic, John A.

AU - Kinney, Marsha C

AU - Hu, Judy Y.

AU - Hamilton, Katherine S.

AU - Greer, John P.

PY - 2003/8/1

Y1 - 2003/8/1

N2 - Background: Large B-cell lymphoma (LBCL) of the leg is an uncommon subset of primary cutaneous B-cell lymphoma that has been described in a series of European patients. Objective: Our purpose was to evaluate the clinical manifestation, diagnostic histopathology, immunophenotype, clinical course, and response to treatment of LBCL of the leg. Methods: We conducted a retrospective case series of 3 patients with primary LBCL of the leg. Results: The 3 elderly patients presented with progressive erythematous nodules on bilateral or unilateral lower extremities. All 3 patients had pre-existing peripheral edema or peripheral vascular disease. Histopathologic examination of the nodules showed dense lymphocytic infiltrates composed predominantly of large dysplastic lymphocytes that marked as B cells (CD20+). In 2 cases, the neoplastic cells were BCL-2 positive. All patients responded to initial therapy with localized electron beam radiation and chemotherapy but had disease progression. One patient had a complete and durable second response to anti-CD20 monoclonal antibody (rituximab). Conclusions: The patients described have similar clinical and histopathologic features to those previously described. There may be an association between LBCL and pre-existing lower-extremity vascular disease. Treatment of LBCL is difficult, but 1 patient responded well to systemic anti-CD20 monoclonal antibody.

AB - Background: Large B-cell lymphoma (LBCL) of the leg is an uncommon subset of primary cutaneous B-cell lymphoma that has been described in a series of European patients. Objective: Our purpose was to evaluate the clinical manifestation, diagnostic histopathology, immunophenotype, clinical course, and response to treatment of LBCL of the leg. Methods: We conducted a retrospective case series of 3 patients with primary LBCL of the leg. Results: The 3 elderly patients presented with progressive erythematous nodules on bilateral or unilateral lower extremities. All 3 patients had pre-existing peripheral edema or peripheral vascular disease. Histopathologic examination of the nodules showed dense lymphocytic infiltrates composed predominantly of large dysplastic lymphocytes that marked as B cells (CD20+). In 2 cases, the neoplastic cells were BCL-2 positive. All patients responded to initial therapy with localized electron beam radiation and chemotherapy but had disease progression. One patient had a complete and durable second response to anti-CD20 monoclonal antibody (rituximab). Conclusions: The patients described have similar clinical and histopathologic features to those previously described. There may be an association between LBCL and pre-existing lower-extremity vascular disease. Treatment of LBCL is difficult, but 1 patient responded well to systemic anti-CD20 monoclonal antibody.

UR - http://www.scopus.com/inward/record.url?scp=0043135048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0043135048&partnerID=8YFLogxK

U2 - 10.1067/S0190-9622(03)00889-2

DO - 10.1067/S0190-9622(03)00889-2

M3 - Article

C2 - 12894069

AN - SCOPUS:0043135048

VL - 49

SP - 223

EP - 228

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 2

ER -